Gut feelings about diabetes and GLP-1 receptor agonists: lessons to be learnt from studies in functional gastrointestinal disorders-Reference-Cited by-同舟云学术

Gut feelings about diabetes and GLP-1 receptor agonists: lessons to be learnt from studies in functional gastrointestinal disorders

Published:2016-12-08 Issue:3 Volume:19 Page:309-312
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Rayner Christopher K.¹,Jones Karen L.¹,Wu Tongzhi¹,Horowitz Michael¹

Affiliation:

1. Discipline of Medicine and Centre of Research Excellence in Translating Nutritional Science to Good Health; University of Adelaide; Adelaide Australia

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/dom.12822/fullpdf

Reference42 articles.

1. Review article: endpoints used in functional dyspepsia drug therapy trials;Ang;Aliment Pharmacol Ther,2011

2. Relationships between gastric emptying, postprandial glycemia, and incretin hormones;Marathe;Diabetes Care,2013

3. Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes;Nielsen;Regul Pept,2004

4. Use of twice-daily exenatide in basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial;Buse;Ann Intern Med,2011

5. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes;Drucker;Lancet,2006

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy and Body Weight in Adults With Overweight or Obesity;JAMA;2021-09-28

2. Energy intake as a short‐term biomarker for weight loss in adults with obesity receiving liraglutide: A randomized trial;Obesity Science & Practice;2021-03-09

3. Glucagon‐like peptide‐1 receptor agonists and the appropriate measurement of gastric emptying;Diabetes, Obesity and Metabolism;2020-09-03

4. A 26-Week Randomized Controlled Trial of Semaglutide Once Daily Versus Liraglutide and Placebo in Patients With Type 2 Diabetes Suboptimally Controlled on Diet and Exercise With or Without Metformin;Diabetes Care;2018-07-19

5. MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study;The Lancet;2018-06